The Roche CUPISCO trial results are being presented at the European Society of Medical Oncologists conference in Spain. The abstract, which gives the details is available on our Blog. The conclusion, which will give evidential weight to support changes in UK standard of care treatment of CUP patients, supports molecularly guided therapy and shows that its use improved progression-free survival for newly diagnosed patients in ‘unfavourable’ sub sets.
CUPISCO trial results. Early genomic profiling extends survival
Category Uncategorized